Chronic granulomatous disease (CGD)' is an uncommon hereditary disorder characterized by recurrent pyogenic infections which usually present early in life and may lead to death in childhood (1) (2) (3) (4) . Phagocytes from CGD patients display normal chemotaxis, ingestion, and degranulation; but microbial killing is deficient (5) . The underlying biochemical defect is the failure of a membrane-associated NADPH oxidase to produce superoxide and related toxic oxygen metabolites (6, 7) .
The phagocyte NADPH oxidase contains a low-midpointpotential b-cytochrome as the terminal electron donor. This heme protein, cytochrome b558, is a heterodimer of a 91 -kD glycoprotein component of the phagocyte oxidase (gp9l-phox) and a 22-kD nonglycosylated polypeptide (p22-phox) (8) . The gene for gp91-phox was one of the first to be identified by positional cloning (9) following localization to X chromosome band Xp2l.1 (10) . Hence, CGD kindreds with the gp9l-phox component affected show X-linked inheritance (11, 12) and in most cases the cytochrome b558 is reduced or absent from their phagocytes (13) .
The gene encoding gp91-phox encompasses 13 exons spanning -30 kb of human X chromosome genomic DNA (14) . Multiple molecular defects producing X-linked CGD have been identified within the coding region and introns of the gene (15) (16) (17) (18) (19) (20) (21) . Such mutations include large, multigene deletions, smaller deletions and insertions, missense and nonsense substitutions, and splicing defects. In 58% of X-linked CGD kindreds (28 of 48 tested), phagocytes express diminished levels of gp9l-phox mRNA (Curnutte, J. T., and P. E. Newburger, manuscript in preparation.); yet, for most such patients, no molecular defects have been identified in PCR-amplified genomic DNA encoding gp9l-phox gene exons (J. T. Curnutte, P. J. Hopkins, and P. E. Newburger, unpublished data).
We have recently identified two kindreds with an unusual form of X-linked CGD (22) and reported in detail the clinical and biochemical characteristics of their phagocytes.2 In the majority of patients with CGD, phagocytes completely lack cytochrome b and exhibit no detectable oxidase activity. Occasional, "variant" forms of X-linked CGD occur, in which low levels (1-25% of normal) of cytochrome b and proportionately decreased oxidase activity are expressed uniformly in all phago-cytes (23) (24) (25) (26) (27) . However, in the two kindreds of the present study, a small subset (5-10%) of neutrophils expressed near normal levels of cytochrome b and oxidase activity, while the remaining cells completely lacked both. Hence the pooled cell oxidase activity was 5-10% of normal, as seen in other forms of "variant" CGD, but the cellular distribution was distinctly different. X-linked inheritance was established by maternal carrier testing. Cytogenetic and restriction fragment length polymorphism analysis demonstrated X chromosome hemizygosity and thus ruled out a sex chromosome abnormality with random X chromosome inactivation as a cause for the observed distribution of activity. Thus, we hypothesized a genetic defect in gp9lphox gene regulation as the cause for this form of CGD.
We have investigated the molecular basis of this apparent defect in the regulation of gp9l-phox expression, and now report two neighboring mutations in the upstream promoter region of the gp9l-phox gene in these kindreds. Both mutations prevent the association of an unidentified DNA-binding protein with oligonucleotide sequences from the promoter region. The functional consequences of the promoter region mutations are impaired transcription of the gp9l-phox gene and utilization, at a decreased rate, of an alternative downstream transcription start site.
Methods
Subjects. The clinical and biochemical characterization of the CGD patients reported in this study have been previously reported in abstract form (22, 28) and in detail elsewhere. 2 Procedures and consent forms were approved by the Committees on the Protection of Human Subjects in Research of the University of Massachusetts Medical Center and The Scripps Research Institute.
Western blots. Immunoreactive quantitation of gp91-phox and p22phox in diisopropylfluorophosphate-treated granulocyte extracts was performed by Western blotting, using previously reported antisera and methodology (29, 30) . Extracts were prepared from the membrane fraction of Percoll gradients (31) and 10 mg from each sample used per lane for polyacrylamide gel electrophoresis. Northern blots. Mixed mononuclear cells were isolated from citrateanticoagulated whole blood by ficoll-hypaque centrifugation (32) . Total cell RNA was extracted from the cells by the guanidine-HCl method (33) and analyzed by Northern blots performed according to standard procedures (34) . Hybridization probes were full-length cDNAs for the human gp91-phox (9), p22-phox (35) (kindly provided by Dr. M. Dinauer, Indiana University Medical Center). Procedures for sequential cycles of prehybridization, hybridization, washes, and filter stripping were performed as described by Gatti, Concannon, and Salser (36) . Equal loading of lanes was demonstrated by examination of gels after ethidium bromide staining and by rehybridization with a 5.8-kb HindmIl restriction fragment of rat 18S ribosomal DNA (37) . Band densitometry was performed by computer image analysis of the integrated optical density of autoradiograph bands, using ImageMeasure software (Microscience, Inc., Federal Way, WA) on an Epson Equity III+ computer, or by direct measurement of 32P decay on a Betascope 603 (Betagen, Waltham, MA) blot analyzer.
Single-strand conformation polymorphism (SSCP) analysis. Genomic DNA was extracted from peripheral blood (34) and analyzed by SSCP as previously described (38, 39) using two-stage nested primer PCR with outer 20-bp oligonucleotide primers with 0.1 g of genomic DNA, then inner primers end-labeled with 32p with the first PCR products as template. The resultant labeled PCR products were visualized by polyacrylamide gel electrophoresis and autoradiography. SSCP analysis was performed on the 5' flanking region and all 13 exons of the gp91-phox gene.
5' end mapping of mRNA transcripts. We adapted the reagents and procedures from the Clontech, Inc. (Palo Alto, CA) 5 '-Ampli-FINDER' RACE (rapid amplification of cDNA ends) Kit (40, 41) .
The basic strategy was to prepare B cell line polyadenylated RNA (34) , reverse transcribe from a primer specific to gp9l-phox nucleotides 600-634, anneal an anchor to the 5' end of the resultant cDNA by singlestranded ligation with T4 RNA ligase in the presence of hexamine cobalt chloride (42) , and then PCR amplify the ligation product using an anchor-specific forward primer and successive nested reverse primers corresponding to nucleotides 417-434 and 375-405. The PCR products were analyzed by agarose gel electrophoresis and sequenced after subcloning into pBluescript (Stratagene, La Jolla, CA).
DNA sequencing. Genomic DNA was isolated from peripheral blood leukocytes by standard methods (34) and amplified by PCR using synthetic oligonucleotide primers designed to amplify the 5 '-flanking region or each of the first 12 (coding region) exons of the gp9l-phox gene. Alternatively, coding region segments were amplified from cDNA prepared by reverse transcription (Pharmacia First-Strand cDNA Synthesis Kit; Pharmacia Fine Chemicals, Piscataway, NJ) of mononuclear cell RNA, prepared as above. Amplified segments were subcloned into pUC19 or related plasmids and bidirectional dideoxy sequencing of the double-stranded DNA was performed by standard methods (34) .
DNA sequence data were repetitively confirmed by sequencing the same segments of DNA in different laboratories (Scripps and University of Massachusetts) using different PCR primers.
Gel shift assays. The myelomonoblastic PLB985 cell line (43) was the generous gift of Thomas Rado (Department of Medicine, University of Alabama at Birmingham). These cells were grown in RPMI medium supplemented with 10% fetal calf serum, 0.2 mM glutamate, 50 U/ml penicillin, and 50 ttg/ml streptomycin. Differentiation of PLB985 cells along the granulocytic lineage was performed by the addition of 1 ,OM retinoic acid for 24 h followed by 60 mM dimethylformamide for 24 h.
Nuclear extracts were prepared as described by Dignam et al. (44) . Complementary oligonucleotides were annealed and end-labeled with [y-32P]ATP as previously described (14) . All oligonucleotides were synthesized so that annealed strands contain BamHI overhangs at their ends. Gel shift assays were carried out by adding nuclear extract (3) (4) (5) ,0g) to 18 ul of buffer [10 mM Tris (pH 7.5), 50 mM K-glutamate, 5 mM MgCl2, 1 mM dithiothreitol, 1 mM EDTA, 5% glycerol, 50 mM poly[d(IC)], and competitor double-stranded oligonucleotides where indicated], and the mixture was preincubated on ice for 15 min. Approximately 5-10 x 103 dpm of probe was then added to each sample and incubation on ice was continued for 15 min. Samples were loaded onto a 0.5x TBE [45 mM Tris (pH 8.3), 45 mM borate, 1.25 mM EDTA], 3.5% nondenaturing polyacrylamide gel, and electrophoresis was carried out at 4°C until the free probe was at the bottom of the gel. Gels were then dried and autoradiography was performed.
Results
We studied one patient (here designated P) from one kindred and two brothers (designated Bl and B2) from another, unrelated kindred with an unusual form of CGD with low levels of residual oxidase activity (22) . The clinical and biochemical characterization of these CGD patients are reported in detail elsewhere.2
To investigate levels of cytochrome b558 protein components, we examined western blots of neutrophil extracts, illustrated in Fig neutrophils showed markedly decreased, but detectable, levels of immunoreactive gp9l-phox and p22-phox. These results indicate that the patients have a cytochrome b negative form of CGD, with slight retention of immunoreactive cytochrome components consistent with the low residual oxidase activity in the cells. However, deficiency of either cytochrome component destabilizes the other member of the heterodimer (45), so the Western blot results are equally consistent with an X-linked defect in the gene encoding gp9l-phox production or with autosomal mutations in both alleles of the p22-phox gene. Northern blot analysis demonstrated the levels of gp9l-phox mRNA transcripts in the patients' and normal peripheral blood mononuclear cells. As shown in Fig. 2 a gp91-phox expression was reduced in the patients' cells, compared to the normal control lane at the far right. The Northern blot hybridization of full length gp9l-phox cDNA probe to each patient's RNA showed a relative preservation of a slightly more rapidly migrating transcript that is usually overshadowed by the predominant larger 4.7-kb band in RNA from normal phagocytes. It is best illustrated in autoradiograph in Fig. 2 b, which represents a Northern blot of RNA analyzed by long duration, low voltage electrophoresis in an 0.8% agarose-formaldehyde gel to maximize separation of the two bands.
All three patients' mononuclear cells expressed normal levels of mRNA for p22-phox, the other component of the cytochrome b558 heterodimer, shown in Fig. 2 . HeLa cell RNA, which served as a negative control for gp9l-phox expression, demonstrates transcripts for p22-phox, which is expressed in a wide variety of nonphagocytic cells (35).
In order to investigate the nature of the shorter transcript that was preferentially expressed in the CGD cells, we amplified segments of cDNA produced by reverse transcription of RNA from each patient. We utilized lymphoblastoid B cell lines created by Epstein-Barr virus infection of the patients' peripheral blood lymphocytes in order to harvest enough RNA for purification of the polyadenylated RNA fraction, which is enriched in messenger RNA. B cell lines from normal individuals express phagocyte oxidase activity; but those derived from CGD patients show biochemical and molecular defects similar to those of the patients' phagocytes (46) . Thus, they can serve as in vitro models of CGD cells and as sources for large harvests of CGD patient nucleic acid. We confirmed that Northern blots from these cells showed the same pattern of gp91-phox expression as that observed from fresh peripheral blood mononuclear cells (data not shown). All PCR products from primers corresponding to the gp91-phox cDNA sequence were normal in size. We next amplified the 5' ends of the transcripts by utilizing a forward primer corresponding to an anchor annealed to the 5' end of each cDNA. The resultant products, shown in Fig. 3 , demonstrated that an alternative transcript, -200 bp shorter than normal, was expressed along with the normal product in B cell lines from each kindred. The shorter product, which was NI P B2 bp -1000 barely detectable in normal cells, appeared at greater or equal proportion to the normal product in the patient samples. These results were confirmed by 5' RACE analysis of whole cell RNA extracts from peripheral blood mononuclear cells.
Sequencing of the short PCR products showed, as in the example presented in Fig. 4 , gp91-phox sequence starting at nucleotide 190, then a guanine residue, followed by the ligated anchor sequence. This finding indicates that transcription of this mRNA species began at an alternative initiation site (cDNA nucleotide 190) within the third exon of the gp91-phox gene and was normally capped with a guanine residue at the 5' end (47) . Some 5 'RACE amplifications from members of each kindred also produced a less abundant, shorter product beginning at cDNA nucleotide 255, also within the third exon.
To determine whether mutations in the regulatory region of the gp91-phox gene could be responsible for its diminished expression in these patients, we screened the 5' (upstream) flanking region of the gene by single strand conformation polymorphism (SSCP) analysis of PCR-amplified genomic DNA. As shown in Fig. 5 , single strand electrophoretic mobility of this segment of gp9l-phox genes from patients B1 and B2, but not P, differed from normal (lane N) and from patterns seen in 1 2 PBB3 4 5 6 7 8 9N Figure 5 . SSCP analysis of the 5' flanking region of the gp9l-phox gene. SSCP analysis was performed, as described in Methods, on genomic DNA extracted from peripheral blood leukocytes. The gel mobility of resultant 32P-labeled PCR products was visualized by autoradiography. The lanes represent, as indicated on the lower margin, SSCP products from patients P. Bl, and B2; normal donors (N); and nine CGD patients with mutations in other regions of the gp91-phox gene (1) (2) (3) (4) (5) (6) (7) (8) (9) . other X-linked CGD patients (lanes labeled with numbers 1-9). The SSCP abnormality was not detected in any of 40 other normal gp9l-phox genes; thus the B family mutation was associated with the CGD phenotype of these kindreds and did not appear to be a commonly occurring polymorphism of the gp9lphox gene. The normal pattern in patient P does not necessarily imply a normal sequence in the 5' flank, since not all base changes result in alterations of SSCP mobility. We therefore examined the region in more detail by DNA sequencing.
Genomic sequencing demonstrated a single base change associated with CGD in each kindred: in patient B, adenine to cytosine at base pair -57 (i.e., 57 bp upstream from the transcription site); and in family P, thymidine to cytosine at base pair -55 (indicated in Fig. 6 ). These closely adjoining mutations are located in between the "CCAAT box" consensus sequences and a partial "TATA box" element (see Discussion) that serve as recognition sites for DNA-binding proteins essential for the transcription of gp9l-phox ( 14) as well as myriad other eukaryotic genes (48) . Examination of all 13 exons of the gp9l-phox gene by SSCP and DNA sequencing did not reveal any coding region abnormalities in the patients.
Gel shift assays were performed to determine directly whether the gp9l-phox promoter mutations identified in these CGD patients affect interactions with DNA-binding proteins. Fig. 7 shows that two specific DNA/protein complexes (indicated by arrows) are formed when a 39-nucleotide region of the gp9l-phox promoter region (-30 to -68) is used as a probe and mixed with nuclear extract isolated from PLB985 cells (lane 2). These two bands are specific, as they are eliminated by competition with an -100-fold excess of unlabeled doublestranded homologous oligonucleotide (lane 3), but are unaffected by the addition of heterologous oligonucleotide (lane 4). Importantly, the faster migrating of these two complexes (solid arrow) is abolished when oligonucleotides containing either of the identified gp9l-phox promoter mutations is used as a probe (lanes 5 and 6). The absence of the faster migrating complex appears to enhance the slower DNA/protein complex in these lanes.
Discussion
Multiple molecular defects within the coding region and introns of the gp9l-phox gene can lead to X-linked CGD (15 viously reported mutations include large, multigene deletions ( 16, 49) , smaller deletions and insertions leading to frameshifts (50), missense and nonsense substitutions (18, 19) , and splicing errors (20, 21) . However, many cases of X-linked CGD are characterized by diminished levels of gp9l-phox mRNA and thus could derive from mutations in regulatory regions governing transcription of the gene (although defects in RNA processing or stability are also possible). In this study, we have identified two mutations at base pairs -55 and -57 in the gp91phox promoter region. Each is associated with X-linked CGD with diminished expression of immunoreactive protein and gp9l-phox mRNA, with relative preservation of transcription initiation at an alternative start site at nucleotide 190 of the normal cDNA sequence. Each mutation abolishes the association of oligonucleotides corresponding to the gp9l-phox promoter region with a DNA-binding protein detectable on gel shift assay. Hence, absence of protein binding appears to be causally related to the diminution of gp9l-phox expression and to the development of CGD in patients carrying these promoter mutations.
The region of gp9l-phox gene flanking sequence in which the mutations and protein binding occur lies in between the well-characterized consensus sequences of a duplicated CCAAT box and a TATA box (see Fig. 6 ). However, the TATA box in this promoter region does not meet minimum requirements for TATA box binding factor: T82A97T93A85(A or T)1ooA83(A or T)100, where the subscript indicates the percent occurrence of the indicated nucleotide (51) . Thus, it is not clear whether the partial consensus TATA box actually functions in transcription initiation by RNA polymerase II, nor whether the lack of full consensus sequence at this location contributes to the instability of the site of transcriptional initiation in the promoter region mutations.
Previous studies of the gp9I-phox promoter region have identified a CCAAT displacement protein that binds to the region around the CCAAT box and interferes with CP1 binding (14) . These DNA-binding proteins, CCAAT displacement factor and CP1, respectively repress and (probably) enhance gp9Iphox expression. The TATA box is a highly conserved sequence motif that is critical for promoter activity and initiation of transcription by RNA polymerase 11 (48) .
As shown in the gel shift assay presented in Fig. 7 , the absence of the faster migrating of the two DNA-protein complexes appears to enhance the amount of oligonucleotide bound in the slower-migrating complex. This finding suggests that these two DNA-binding proteins compete for binding. However, no firm conclusions can be reached, as the specific activity of the probes may differ. More detailed characterization of these DNA-binding proteins is in progress to address this question. The protein responsible for the faster-migrating complex is detectable in cell lines representing both myeloid and nonmyeloid hematopoietic lineages, but has not yet been found in nonhematopoietic cells (Eklund, E. A., and D. G. Skalnik, manuscript submitted for publication). Thus, further investigation will also be needed to define its role and interactions with other transcription factors in the regulation of gp9l-phox and possibly other myeloid-specific genes.
The data also imply a relationship between the fine structure of the promoter region and the position for initiation of transcription, presumably mediated by the DNA-binding protein(s) that associate with the sequence mutated in these CGD kindreds. Transcription from the alternative start site, which is a barely detectable product of normal transcription, appears relatively unaffected by the mutations and hence becomes a major product in the CGD cells. Although only 190 nt downstream from the start of the normal cDNA, the site is located in the third exon of the gp9l-phox gene, so its position is actually 3.2 kb from the normal site in genomic DNA, due to the additional two intervening sequences of 1.9 and 1.1 kb. Examination of the exon and intron sequence upstream from the alternative start site reveals a possible SP-1 binding site in the second intron, 45 nt upstream from the nt 190 alternative transcription start site, but no other sequence elements associated with 5' regulatory regions.
Translation of the transcript could theoretically yield a protein product lacking the normal gp9l-phox amino terminal sequence, utilizing the in-frame ATG codon at position 205 (seen at the top of the marginal sequence in Fig. 4 ) or that at position 319, which is associated with a Kozak consensus sequence for translational initiation (9) . The lack of detection of such a polypeptide on the Western blots, such as that in Fig. 1 , could indicate either instability or insufficient synthesis of such an abnormal gene product.
The connection between the molecular effects of the mutations and the cellular CGD phenotype in these kindreds remains obscure. As presented in detail elsewhere,2 the patients have a rare, "variant" form of the disease characterized by near normal expression of phagocyte oxidase activity in a small subset (5-10%) of neutrophils and no activity in the remaining cells. We speculate that this manifestation of neutrophil heterogeneity may reflect the utilization of different DNA binding proteins for the enhancement or initiation of gp9l-phox transcription by the subpopulation unaffected by the mutations. The promoter region mutations reported in the present study extend the inventory of molecular changes responsible for CGD to regulatory defects that interfere with mRNA transcription. They have also served as "experiments of nature" that both demonstrate the importance of the gp9l-phox promoter region sequence between the CCAAT and TATA boxes and help detect one or more previously unknown DNA-binding proteins that associate with this sequence element.
